TGFB1 and esophageal adenocarcinoma: Thus, block TGF-β signaling can increase the anti-tumor efficacies of trastuzumab and pertuzumab in esophageal adenocarcinoma cells and xenograft tumors (Ebbing et al., 2017; Ebbing et al., 2019; Steins et al., 2019).